The Brussels Development Briefing no. 52 on “Food safety: a critical part of the food system in Africa ” took place on 19 September 2018 from 09h00 to 13h00, ACP Secretariat, Brussels 451 Avenue Georges Henri, 1200 Brussels. This Briefing was organised by the ACP-EU Technical Centre for Agricultural and Rural Cooperation (CTA), in collaboration with the European Commission (DG DEVCO & DG Health and Food Safety), the ACP Secretariat, CONCORD and the Global Food Safety Partnership.
Zoonotic diseases is the rare disease that is usually spread from faunas to humans and from humans to faunas. There are various ways of disease being transferred, such as air by direct contact, by contact with an inert object that harbors the disease, oral ingestion, and by insect. The diseases from wiretaps and other faunas can make sick or death in people. Many health agencies globally have track on the disease and death caused by zoonotic disease. The animals always carry some or the other infective pathogens that can be shared or transmitted with/ to people. Zoonotic diseases may be caused by germs which including bacteria, viruses, parasites, and fungi. Zoonoses when infected can lead to many different types of illnesses in humans and faunas which can be mild to severe that human or animal may die. It is always important to notice that the faunas do not always appear ill or sick when carrying a zoonotic disease, many animals do appear healthy, but they still carry infectious germs that can make people sick.
Zoonotic diseases has become very common now a days throughout the globe. Scientist’s assessment about the zoonotic diseases are that more than 8 out of every 12 known infectious diseases in humans are spread from faunas, and 4 out of every 5 new or emerging infectious diseases in people are spread from faunas. Yearly, estimated, thousands of Americans gets sick from diseases spread between faunas and humans. Because of this, the national health agency works 24/7 to protect people from zoonotic diseases.
mHealth Israel_Medical Devices in Portugal_Rui Costa_GE HealthcareLevi Shapiro
Presentation about the Medical Device sector in Portugal by Rui Costa, General Manager- Portugal, GE Healthcare, for the mHealth Israel community, June 2, 2020. Includes current trends, sales data, key changes, challenges, reflections, transitions, collaborations, etc
The Brussels Development Briefing no. 52 on “Food safety: a critical part of the food system in Africa ” took place on 19 September 2018 from 09h00 to 13h00, ACP Secretariat, Brussels 451 Avenue Georges Henri, 1200 Brussels. This Briefing was organised by the ACP-EU Technical Centre for Agricultural and Rural Cooperation (CTA), in collaboration with the European Commission (DG DEVCO & DG Health and Food Safety), the ACP Secretariat, CONCORD and the Global Food Safety Partnership.
Zoonotic diseases is the rare disease that is usually spread from faunas to humans and from humans to faunas. There are various ways of disease being transferred, such as air by direct contact, by contact with an inert object that harbors the disease, oral ingestion, and by insect. The diseases from wiretaps and other faunas can make sick or death in people. Many health agencies globally have track on the disease and death caused by zoonotic disease. The animals always carry some or the other infective pathogens that can be shared or transmitted with/ to people. Zoonotic diseases may be caused by germs which including bacteria, viruses, parasites, and fungi. Zoonoses when infected can lead to many different types of illnesses in humans and faunas which can be mild to severe that human or animal may die. It is always important to notice that the faunas do not always appear ill or sick when carrying a zoonotic disease, many animals do appear healthy, but they still carry infectious germs that can make people sick.
Zoonotic diseases has become very common now a days throughout the globe. Scientist’s assessment about the zoonotic diseases are that more than 8 out of every 12 known infectious diseases in humans are spread from faunas, and 4 out of every 5 new or emerging infectious diseases in people are spread from faunas. Yearly, estimated, thousands of Americans gets sick from diseases spread between faunas and humans. Because of this, the national health agency works 24/7 to protect people from zoonotic diseases.
mHealth Israel_Medical Devices in Portugal_Rui Costa_GE HealthcareLevi Shapiro
Presentation about the Medical Device sector in Portugal by Rui Costa, General Manager- Portugal, GE Healthcare, for the mHealth Israel community, June 2, 2020. Includes current trends, sales data, key changes, challenges, reflections, transitions, collaborations, etc
Immuron Ltd is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that is capable of generating a wide range of products, all with a high safety profile. The versatility of Immuron’s platform technology enables the development of medicines that target a large range of medical needs, including infectious diseases, immune mediated disorders, and cancers. The versatility is also a function of the dairy origin of Immuron’s antibodies, which enables Immuon to commercialize its platform derived products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company has received clearance from the FDA to commence a Phase IIb clinical trial for its NASH product (IMM-124E), a potential blockbuster, in less than three years from commencing its NASH R&D program. Additionally, Immuron has one marketed product (Travelan, for the prevention of travelers’ diarrhea) and a pipeline of products at various stages of clinical and earlier development.
Mediterranean Treasures, import & export platform for quality gourmet products form Portugal, Spain, Italy and Greece. Our port folio is selected for Delicacies, Organic and Foodservices companies in the Benelux, Middle East and Asia. Our idea is to inform our customers and their customers that we have the opportunity and aibilty to start with more focus on healthy, tastefully and particular sustainable production of food and ingredients. Lets try and find together new directions and discover the amazing taste and values for our love ones.
This publication provides information on the use of price policies to promote healthy diets and explores policy developments from around the WHO European
Region. It examines the economic theory underpinning the use of subsidies and taxation and explores the currently available evidence. The publication includes
several case studies from WHO European Member States where price policies have been introduced. It concludes with some observations about the design of
more effective price policies.
Europe's Pioneering Leaders Shaping the Future of Healthcare.pdfeurohealthleaders
Euro Health Leaders’ recent edition Europe’s Pioneering Leaders Shaping the Future of Healthcare, introduces you to the individuals driving transformative technologies, from integrating artificial intelligence in diagnostics to the revolutionary impact of biotechnology on treatment modalities.
Working in Global HealthChapter 18Chapter 18 Working irosacrosdale
Working in Global Health
Chapter 18
Chapter 18: Working in Global Health
1
Positions in Global Health
Universities
NGOs
Social entrepreneurships
Bilateral and multilateral aid organizations
Consulting
Global health is a growing field and there are many opportunities to work in it.
2
When considering a job in Global health
Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
If you are considering a job in global health, you should: Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
3
Other valuable points
Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
Other things to consider are: Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
4
Resources for careers
DEVEX http://globalhealth.org/
The Global Health Council http://globalhealth.org/
Global Health Hub www.globalhealthhub.org
International Jobs Center http://www.internationaljobs.org/
Idealist www.idealist.org
U.S Government
USAID https://www.usaid.gov/
CDC http://www.cdc.gov/
Here are a few resources to consider when looking for a career in global health.
5
Personal Quote
“Working in global health has been my dream as long as I can remember. And just imagine how reality could be better than a dream- and that’s exactly how I feel working in this field. It’s the most fulfilling career that I could ever imagine.”
Dr. Tara Rava Zolnikov
Assistant Professor
National University
Water project in Narok, Kenya
HIV/AIDS project in Busia, Kenya
Access to water research in Kitui, Kenya
Science, Technology, and Global Health
Chapter 17
1
Chapter 17: Science, Technology, and Global Health
The Need for New Products
Characteristics of new technologies must reflect the following:
Most important target groups are poor people.
Quality of care and injection safety is often low.
Many low- and middle-income countries have poorly organized health systems.
Science and technology ...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...Thelansis
Thelansis known to provide therapy specific market insight reports which essentially covers Epidemiology and Market Forecast of 8 key markets (US, Germany, France, Spain, Italy, UK, Japan and China) in a advance excel based dynamic forecast model, enables client to understand the differnet scenario of the market over a period of 10 years.
Competitive landscape analysis covered in the Thelansis reports allows our clients to monitor competitor’s activity around targeted indications during a different phase of development (Early Phase, Phase I, II, and III) and post-approval phase.
Our services include epidemiology study, Market forecasting, clinical trial analytics, Pipeline assessment, enrollment projections, trialsite prioritization, investigator profiling, and trial completion date projection, launch date estimation, and essentially the key product positioning.
Thelansis reports now coupled with KOL insights gathered from the the Primary market research (PMR) through in-house programmed web-based survey tool which helps our clients to fill the gap of real-time data, unmet needs, and critical strategic insights right from development to commercialization.
Presented by Philip James of the London School of Hygiene and Tropical Medicine at the WHO European Ministerial Conference on Nutrition and Noncommunicable Diseases in the Context of Health 2020 on 4 July 2013 in Vienna, Austria.
Disclaimer: WHO is not responsible for the content of presentations made by external speakers at its meetings and conferences. This presentation is published here with the speaker's consent, only for information purpose.
Ομιλία – Παρουσίαση: Daphné Lecomte-Somaggio, General Manager of AFIPA, the French Association of Pharmaceutical Industry for Responsible self-medication
«French Position on Self-medication»
Food safety in low- and middle-income countries: What works, what doesn't and...ILRI
Presentation by Delia Grace, Fred Unger, Hung Nguyen-Viet, Johanna Lindahl, Kohei Makita, Kristina Roesel, Michael Taylor, Ram Deka, Sinh Dang Xuan, Steve Jaffee and Silvia Alonso at the 15th International Symposium of Veterinary Epidemiology and Economics, Chiang Mai, Thailand, 13 November 2018.
Official speaker book for the NOAH 2019 Conference in Tel Aviv with comprehensive background information on all presenting speakers and their companies.
Immuron Ltd is an Australian biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans. Immuron has a unique and versatile technology platform that is capable of generating a wide range of products, all with a high safety profile. The versatility of Immuron’s platform technology enables the development of medicines that target a large range of medical needs, including infectious diseases, immune mediated disorders, and cancers. The versatility is also a function of the dairy origin of Immuron’s antibodies, which enables Immuon to commercialize its platform derived products through a range of regulatory pathways, including prescription (Rx), medical foods, over-the-counter (OTC) medicines, and dietary supplements. The Company has received clearance from the FDA to commence a Phase IIb clinical trial for its NASH product (IMM-124E), a potential blockbuster, in less than three years from commencing its NASH R&D program. Additionally, Immuron has one marketed product (Travelan, for the prevention of travelers’ diarrhea) and a pipeline of products at various stages of clinical and earlier development.
Mediterranean Treasures, import & export platform for quality gourmet products form Portugal, Spain, Italy and Greece. Our port folio is selected for Delicacies, Organic and Foodservices companies in the Benelux, Middle East and Asia. Our idea is to inform our customers and their customers that we have the opportunity and aibilty to start with more focus on healthy, tastefully and particular sustainable production of food and ingredients. Lets try and find together new directions and discover the amazing taste and values for our love ones.
This publication provides information on the use of price policies to promote healthy diets and explores policy developments from around the WHO European
Region. It examines the economic theory underpinning the use of subsidies and taxation and explores the currently available evidence. The publication includes
several case studies from WHO European Member States where price policies have been introduced. It concludes with some observations about the design of
more effective price policies.
Europe's Pioneering Leaders Shaping the Future of Healthcare.pdfeurohealthleaders
Euro Health Leaders’ recent edition Europe’s Pioneering Leaders Shaping the Future of Healthcare, introduces you to the individuals driving transformative technologies, from integrating artificial intelligence in diagnostics to the revolutionary impact of biotechnology on treatment modalities.
Working in Global HealthChapter 18Chapter 18 Working irosacrosdale
Working in Global Health
Chapter 18
Chapter 18: Working in Global Health
1
Positions in Global Health
Universities
NGOs
Social entrepreneurships
Bilateral and multilateral aid organizations
Consulting
Global health is a growing field and there are many opportunities to work in it.
2
When considering a job in Global health
Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
If you are considering a job in global health, you should: Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
3
Other valuable points
Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
Other things to consider are: Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
4
Resources for careers
DEVEX http://globalhealth.org/
The Global Health Council http://globalhealth.org/
Global Health Hub www.globalhealthhub.org
International Jobs Center http://www.internationaljobs.org/
Idealist www.idealist.org
U.S Government
USAID https://www.usaid.gov/
CDC http://www.cdc.gov/
Here are a few resources to consider when looking for a career in global health.
5
Personal Quote
“Working in global health has been my dream as long as I can remember. And just imagine how reality could be better than a dream- and that’s exactly how I feel working in this field. It’s the most fulfilling career that I could ever imagine.”
Dr. Tara Rava Zolnikov
Assistant Professor
National University
Water project in Narok, Kenya
HIV/AIDS project in Busia, Kenya
Access to water research in Kitui, Kenya
Science, Technology, and Global Health
Chapter 17
1
Chapter 17: Science, Technology, and Global Health
The Need for New Products
Characteristics of new technologies must reflect the following:
Most important target groups are poor people.
Quality of care and injection safety is often low.
Many low- and middle-income countries have poorly organized health systems.
Science and technology ...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...Thelansis
Thelansis known to provide therapy specific market insight reports which essentially covers Epidemiology and Market Forecast of 8 key markets (US, Germany, France, Spain, Italy, UK, Japan and China) in a advance excel based dynamic forecast model, enables client to understand the differnet scenario of the market over a period of 10 years.
Competitive landscape analysis covered in the Thelansis reports allows our clients to monitor competitor’s activity around targeted indications during a different phase of development (Early Phase, Phase I, II, and III) and post-approval phase.
Our services include epidemiology study, Market forecasting, clinical trial analytics, Pipeline assessment, enrollment projections, trialsite prioritization, investigator profiling, and trial completion date projection, launch date estimation, and essentially the key product positioning.
Thelansis reports now coupled with KOL insights gathered from the the Primary market research (PMR) through in-house programmed web-based survey tool which helps our clients to fill the gap of real-time data, unmet needs, and critical strategic insights right from development to commercialization.
Presented by Philip James of the London School of Hygiene and Tropical Medicine at the WHO European Ministerial Conference on Nutrition and Noncommunicable Diseases in the Context of Health 2020 on 4 July 2013 in Vienna, Austria.
Disclaimer: WHO is not responsible for the content of presentations made by external speakers at its meetings and conferences. This presentation is published here with the speaker's consent, only for information purpose.
Ομιλία – Παρουσίαση: Daphné Lecomte-Somaggio, General Manager of AFIPA, the French Association of Pharmaceutical Industry for Responsible self-medication
«French Position on Self-medication»
Food safety in low- and middle-income countries: What works, what doesn't and...ILRI
Presentation by Delia Grace, Fred Unger, Hung Nguyen-Viet, Johanna Lindahl, Kohei Makita, Kristina Roesel, Michael Taylor, Ram Deka, Sinh Dang Xuan, Steve Jaffee and Silvia Alonso at the 15th International Symposium of Veterinary Epidemiology and Economics, Chiang Mai, Thailand, 13 November 2018.
Official speaker book for the NOAH 2019 Conference in Tel Aviv with comprehensive background information on all presenting speakers and their companies.
Official speaker book for the NOAH 2018 Conference in Tel Aviv with comprehensive background information on all presenting speakers and their companies.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
6. Why do only travelers and not locals suffer from TD?
7. Because their gut has not adapted to the
foodborne bacteria it is facing
8. Diarrhea remains to be a major problem to individuals in various situations
55% of people traveling to developing countries are affected
Highest risk regions are Africa, the Middle East, South Asia & Latin America
Food and water contaminated with fecal matter is the main reservoir for pathogens
The major pathogen in TD are bacteria. These however, vary strongly between
geographic regions
- Strictly Confidential -
9. • Only offering symptomatic treatment
• Narrow therapeutic window, resulting in constipation when overdosed
• Multiple recorded side effects
• Should not be used without medical supervision
• Result in resistant bacteria if used too frequently
Synbiotics
• No recorded side effects
• Repopulate the healthy intestinal microbiome
• Acts preventively
• Causal instead of symptomatic treatment
Opioids
Antibiotics
No drugs address diarrhea treatment with regard to its specific cause
- Strictly Confidential -
10. mybacs uses the unique pathogenic profile of high risk travel regions to offer
specific treatment
Geographically
specific
treatment
Very safe,
classified as a
food supplement
Unique &
intuitive
packaging
- Strictly Confidential -
12. mybacs targets 5 verticals within the microbiome sphere
Daily well-beingTravel Dietary change Smoking Antibiotics
ü
Launched in
February 2019
Projected launch
Q3 2019
Projected launch
Q1 2020
Projected launch
Q3 2020
Projected launch
Q1 2021
13. Meet the Founders
Sebastian Wahl
Founder & Co-CEO
• M.Sc. with distinction in Medicinal and Industrial
Pharmaceutical Sciences from ETH Zurich
• Scientist at FOG Pharmaceuticals developing a
new cancer treatment
• Work experience in Venture Capital and Strategy
Consulting
Carl-Philipp von Polheim
Founder & Co-CEO
• M.Sc. with distinction in Management from ESCP
Europe
• Worked as an Investment Banking Analyst in the
technology sector with a focus on corporate
financing and M&A
• Work experience in Startups and Private Equity
- Strictly Confidential -
14. Status quo
o 2 offices in Zug and Munich
o CHF 240k in funding from Angels
Funding & Financials
Partnerships
Company
Market
o Founded in August 2018, launched in February 2019
o 6 Team members in the fields of Pharma & Business
o Current monthly run-rate: € 10.000 (3 months post launch)
o +1000 Travelbacs sold
o Probiotics Global: $ 32bn
o Probiotics Europe: $ 12bn
o CAGRs: 7– 9 %
15. Thank You – Let’s get in touch
- Strictly Confidential -
Sebastian Wahl
Fon: +49 152 226 900 30
Email: sebastian@mybacs.co
Carl-Philipp von Polheim
Fon: +49 173 362 76 19
Email: carl@mybacs.co
Zugerstrasse 76B
6340 Baar
mybacs.co